《大行報告》大摩相信中國中藥(00570.HK)股價未來45日內將升 評級「增持」
摩根士丹利發表研究報告指,中國中藥(00570.HK)近期被低估,短期估值具吸引力,相信股價在未來45天有70%至80%機率會上升。
報告指出,明年首季配方顆粒產品價格預期將上升,認為中國中藥在新年假期前將獲得重新估值。該行指,以2022年預測市盈率計,中國中藥目前被低估約7倍,估計2020至2023年盈利複合年增長率為19%,並預計市場份額將持續提升。大摩給予中國中藥「增持」評級,目標價6.3元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.